Swiss health technology company Roche has introduced two new analytical units for the Cobas pro integrated solutions, cobas C 703 and cobas ISE neo, in countries accepting the CE mark.

The cobas c 703 and cobas ISE neo analytical units provide advanced features to address some of the key challenges faced by diagnostic laboratories worldwide.

Launched in 2018, Roche’s cobas pro integrated is a scalable and modular diagnostic platform designed to meet mid-to-very-high volume clinical immunochemistry testing needs.

It features cobas AutoCal, an automated calibration procedure that saves hands-on time, cobas SonicWash, an ultrasonic probe cleaning, along with automated maintenance.

Building on its rapid analytical units, intelligent sample routing, and short assay incubation times, the solution aims to enhance testing efficiency.

The cobas pro integrated solutions is fully compatible with the cobas mobile solutions and can be easily integrated into Roche’s clinical chemistry and immunochemistry testing.

Roche Diagnostics CEO Matt Sause said: “Today more than ever, accurate and timely diagnostics is critical for effective delivery of healthcare. Labs are under increasing pressure to process more samples, at greater speed without compromising accuracy.

“With the launch of the cobas c 703 and cobas ISE neo, we are taking our latest generation clinical chemistry and immunochemistry platform, the cobas pro integrated solutions, to the next level.

“By integrating high-volume clinical chemistry testing and increased automation, we will set a new standard for high-volume testing in the clinical lab.”

The new cobas c 703 analytical unit is designed to double the clinical chemistry throughput on cobas pro integrated solutions, with up to 2,000 tests per hour and 70 reagent positions.

The enhanced onboard reagent capacity enables more high-value tests while improving workflow efficiency and saving time spent reloading reagents.

Cobas ISE neo is designed to improve ion selective electrode (ISE) testing efficiency, offering up to 1,800 tests per hour.

The new unit comes with several advanced hardware and software features, including an automated calibration concept, to significantly reduce the need for manual intervention.

It also offers more tests per reagent bottle, reducing the bottle changing frequency, minimising plastic waste, and reducing logistical efforts compared to previous generation systems.

Roche said that by automating the work, the newly introduced units will further improve lab efficiency, address the shortage of staff, and enhance the delivery of tests to the people.

Recently, Roche has launched a new in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in CE Mark accepting countries.